Статья
Сочетание фибрилляции предсердий и обструктивного апноэ сна — есть ли связь?
В обзорной статье обсуждается вопрос о взаимном влиянии фибрилляции предсердий (ФП) и обструктивного апноэ сна (ОАС) при сочетанном течении этих заболеваний. У лиц с сочетанием данных патологий ОАС может влиять на более легкую реализацию ФП. Наличие нарушений дыхания во сне снижает эффективность всех видов лечения ФП (антиаритмическое, хирургическое, электрическая кардиоверсия). Показано, что лечение ОАС методом неинвазивной вентиляционной поддержки (CPAP-терапия) улучшает результаты катетерного лечения ФП в раннем послеоперационном периоде.
1. Van Wagoner DR, Piccini JP, Albert CM, et al. Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. Heart Rhythm. 2015;12(1):e5-29. doi:10/2016/j.hrthm.2014.11.011.
2. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213-20. doi:10.2147/CLEP.S47385.
3. Wong CX, Brooks AG, Leong DP, et al. The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia. Arch Intern Med. 2012;172(9):739-41. doi:10.1001/archinternmed.2012.878.
4. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34:2746-51. doi:10.1093/eurheartj/eht280.
5. Haim M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4:e001486. doi:10.1161/JAHA.114.001486.
6. McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. Circulation. 2012;126:e143-6. doi:10.1161/CIRCULATIONAHA.112.129759.
7. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167:1807-24. doi:10.1016/j.ijcard.2012.12.093.
8. Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44:3103-8. doi:10.1161/STROKEAHA.113.002329.
9. Andersson T, Magnuson A, Bryngelsson IL, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J. 2013;34:1061-7. doi:10.1093/eurheartj/ehs469.
10. Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384:2235-43. doi:10.1016/S0140-6736(14)61373-8.
11. Henriksson KM, Farahmand B, Asberg S, et al. Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. Int J Stroke. 2012;7:276-81. doi:10.1111/j.1747-4949.2011.00706.x.
12. Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke. 2013;44:3357-64. doi:10.1161/STROKEAHA.113.001884.
13. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF’. Eur Heart J. 2009;30:2969-77c. doi:10.1093/eurheartj/ehp235.
14. Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirintreated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36:281-7a. doi:10.1093/eurheartj/ehu307.
15. Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J. 2015;36:288-96. doi:10.1093/eurheartj/ehu359.
16. Manolis AJ, Rosei EA, Coca A, et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension. J Hypertens. 2012;30:239-52. doi:10.1097/HJH.0b013e32834f03bf.
17. Guha K, McDonagh T. Heart failure epidemiology: European perspective. Curr Cardiol Rev. 2013;9:123-7. doi:10.2174/1573403X11309020005.
18. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J. 2015;36:3250-7. doi:10/1093/eurheartj/ehv513.
19. Vahanian A, Alfieri O, Andreotti F, et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:2451-96. doi:10/1093/eurheartj/ehs109.
20. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2438-88. doi:10.1161/CIR.0000000000000029.
21. Huxley RR, Misialek JR, Agarwal SK, et al. Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol 2014;7:620-5. doi:10.1161/CIRCEP.113.001244.
22. Hart RG, Eikelboom JW, Brimble KS, et al. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol. 2013;29:S71-8. doi:10.1016/j.cjca.2013.04.005.
23. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal 2016;37(38):2893-962. doi:10.1093/europace/euw295.
24. Fatemi O, Yuriditsky E, Tsioufis C, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol. 2014;114:1217-22. doi:10.1016/j.amjcard.2014.07.045.
25. Chang S-H, Wu LS, Chiou MJ, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13:123. doi:10.1186/s12933-014-0123-x.
26. Digby GC, Baranchuk A. Sleep apnea and atrial fibrillation; 2012 update. Curr Cardiol Rev. 2012;8(4):265-72. doi:10.2174/157340312803760811.
27. Vizzardi E, Sciatti E, Bonadei I, et al. Obstructive sleep apnoea-hypopnoea and arrhythmias: new updates. J Cardiovasc Med (Hagerstown). 2014, doi:10.2459/JCM.0000000000000043.
28. Heinzer R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med. 2015;3(4):310-8. doi:10.1016/S2213-2600(15)00043-0.
29. Braga B, Poyares D, Cintra F, et al. Sleep-disordered breathing and chronic atrial fibrillation. Sleep Med. 2009;10:212-6. doi:10.1016/j.sleep.2007.12.007.
30. Zhao LP, Kofidis T, Lim TW, et al. Sleep apnea is associated with new-onset atrial fibrillation after coronary artery bypass grafting. J Crit Care. 2015;30(6):1418.e1-1418.e5. doi:10.1016/j.jcrc.2015.07.002.
31. Wong JK, Maxwell BG, Kushida CA, et al. Obstructive sleep apnea is an independent predictor of postoperative atrial fibrillation in cardiac surgery. J Cardiothorac Vasc Anesth. 2015;29(5):1140-7. doi:10.1053/j.jvca.2015.03.024.
32. Mehra R, Sleep apnea ABCs: airway, breathing, circulation. Cleve Clin J Med. 2014;81:47989. doi:10.3949/ccjm.81gr.14002.
33. Linz D. Atrial fibrillation in obstructive sleep apnea: atrial arrhythmogenic substrate of a different sort. Am J Cardiol. 2012;110:1071. doi:10.1016/j.amjcard.2012.07.001.
34. Lin YK, Lai MS, Chen YC, et al. Hypoxia and reoxygenation modulate the arrhythmogenic activity of the pulmonary vein and atrium. Clin Sci (Lond) 2012;122:121-32. doi:10.1042/CS20110178.
35. Patel D, Mohanty P, Di Biase L, et al. Safety and efficacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: The impact of continuous positive airway pressure. Circ Arrhythm Electrophysiol. 2010;3:445-51. doi:10.1161/CIRCEP.109.858381.
36. Fein AS, Shvilkin A, Shah D, et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol. 2013;62(4):300-5. doi:10.1016/j.jacc.2013.03.052.
37. Naruse Y, Tada H, Satoh M, et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm. 2013;10(3):331-7. doi:10.1016/j.hrthm.2012.11.015.
38. Li L, Wang ZW, Li J, et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies. Europace. 2014;16:1309-14. doi:10.1093/europace/euu066.
39. Heinzer R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med. 2015;3(4):310-8. doi:10.1016/S2213-2600(15)00043-0.
40. Kanagala R, Murali N, Friedman P, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation. 2003;107:2589-94. doi:10.1161/01.CIR.0000068337.25994.21.
41. Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004;110:364-7. doi:10.1161/01.CIR.0000136587.8E.
42. Matiello M, Nadal D, Temporero D, et al. Low efficacy of atrial fibrillation ablation in severe apnoea patients. Europace. 2010;12:1084-9. doi:10.1093/europace/euq128.
43. Altmann DR, Ullmer E, Rickli H, et al. Clinical impact of screening for sleep related breathing disorders in atrial fibrillation. Int J Cardiol. 2012;154:256-8. doi:10.1016/j.ijcard.2010.09.034.
44. Hoyer FF, Lickfett LM, Mittmann-Braun E. High prevalence obstructive sleep apnea in patients with resistant paroxysmal atrial fibrillation after pulmonary vein isolation. J Interv Card Electrophysiol. 2012;29:2462-4. doi:10.1007/s10840-010-9502-8.
45. Tang RB, Dong JZ, Liu XP, et al. Obstructive sleep apnea risk profile and the risk of atrial fibrillation after catheter ablation. Europace. 2009;11:100-95. doi:10.1093/europace/eun315.
46. Stevenson IH, Teichtahl H, Cunnington D, et al. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur Heart J. 2008;29:1662-9. doi:10.1093/eurheartj/ehn214.
47. Goudis CA, Ketikoglou DG. Obstructive sleep and atrial fibrillation: Pathophysiological mechanisms and therapeutic implications. Int J Cardiol. 2016. doi:10.1016/j.ijcard.2016.12.120.
48. Zhang L, Hou Y, Po SS. Obstructive Sleep Apnoea and Atrial Fibrillation. Arrhythmia & Electrophysiology Review. 2015;4(1):14-8. doi:10.15420/aer.2015.4.1.14.
49. Dimitri H, Ng M, Brooks AG, et al. Atrial remodeling in obstructive sleep apnea: implications for atrial fibrillation. Heart Rhythm. 2012;9:321-7. doi:10.1016/j.hrthm.2011.10.017.
50. McGown AD, Makker H, Elwell C, et al. Measurement of changes in cytochrome oxidase redox state during obstructive sleep apnea using near-infrared spectroscopy. Sleep. 2003;26:710-6.
51. Peng Y, Yuan G, Overholt JL, et al. Systemic and cellular responses to intermittent hypoxia: evidence for oxidative stress and mitochondrial dysfunction. Adv Exp Med Biol. 2003;536:559-64.
52. Vgontzas AN, Bixler EO, Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med. 2003; 254:32-44. doi:10.1046/j.1365-2796.2003.01177.x.
53. Goyal SK, Sharma A. Atrial fibrillation in obstructive sleep apnea. World J Cardiol. 2013;5(6):157-63. doi:10.4330/wjc.v5.i6.157.
54. Chen PS, Zipes DP. Lecture. Neural mechanisms of atrial fibrillation. Heart Rhythm. 2006;3:1373-7. doi:10.1016/j.hrthm.2006.08.010.
55. Caples SM, Somers VK. Sleep-disordered breathing and atrial fibrillation. Prog Cardiovasc Dis. 2009;51:411-5.
56. Brunner KJ, Bunch TJ, Mullin CM, et al. Clinical predictors of risk for atrial fibrillation: implications for diagnosis and monitoring. MayoClinProc. 2014;89:1498-505. doi:10.1016/j.mayocp.2014.08.016.
57. Lurie A. Endothelial dysfunction in adults with obstructive sleep apnea. Adv Cardiol. 2011;46:139-70. doi:10.1159/000325108.
58. Chan KH, Wilcox I. Obstructive sleep apnea: a novel trigger for cardiac arrhythmias and potential therapeutic target. Expert Rev Cardiovasc Ther. 2010;8:981-4. doi:10.1586/erc.10.80.
59. Kalifa J, Jalife J, Zaitsev A, et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation. 2003;108:668-71. doi:10.1161/01.CIR.0000086979.39843.7B.
60. Iwasaki Y, Kato T, Xiong F, et al. Atrial fibrillation promotion with long-term repetitive obstructive sleep apnea in a rat model. JACC. 2014;64(19):2013-23. doi:10.1016/j.jacc.2014.05.077.
61. Проничева И. В., Ревишвили А. Ш. Роль коннексинов и натриевого канала NAv1.5, кодируемого геном SCN5A, в нарушениях проведения электрического импульса в миокарде. Вестник Аритмологии. 2012;67:59-62.
62. Linz D, Hohl M, Khoshkish S, et al. Low-Level But Not High-Level Baroreceptor Stimulation Inhibits Atrial Fibrillation in a Pig Model of Sleep Apnea. J Cardiovasc Electrophysiol. 2016;27(9):1086-92. doi:10.1111/jce.13020.
63. Monahan K, Brewster J, Wang L, et al. Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. Am J Cardiol. 2012;110(3):369-72. doi:10.1016/j.amjcard.2012.03.037.
64. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265-325. doi:10.1152/physrev.00031.2009.
65. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861-72. doi:10.1056/NEJMoa041705.
66. Jongnarangsin K, Chuch A, Good E, et AL. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19:668-72. doi:10.1111/j.1540-8167.2008.01118.x.
67. Ng C, Liu T, Shehata M, et al. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol. 2011;108:47-51. doi:10.1016/j.amjcard.2011.02.343.
68. Farrehi PM, O’Brien LM, Bas HD, et al. Occult obstructive sleep apnea and clinical outcomes of radiofrequency catheter ablation in patients with atrial fibrillation. J Interv Card Electrophysiol. 2015;43:279-86. doi:10.1007/s10840-015-0014-4.
69. Abe H, Takahashi M, Yaegashi H, et al. Efficacy of continuous positive airway pressure on arrhythmias in obstructive sleep apnea patients. Heart Vessels. 2010;25:63-9. doi:10.1007/s00380-009-1164-z.